EUVIMEDEuropean Health Evidence
Uhr Sources10/10 Journal Tree
Easy Demo

European Health Evidence

The European alternative to PubMed

EUVIMED is the European alternative to PubMed: a central, multilingual research platform for medicine, nursing, life sciences and healthcare. It brings together international and European literature sources, study registries, open-access full texts, citations and retraction notices in one search. Unlike pure bibliographic databases, EUVIMED supports the entire research process – from discovery and appraisal with LIVIA and CLARA to traceable evidence synthesis. European in focus, transparent, interoperable and designed for science and healthcare.

EuropeanMultilingualInteroperableTraceable

EUVIMED BETA

EUVIMED is currently in beta

EUVIMED is under continuous development. Features, data coverage and presentation may change or be temporarily incomplete.

Results are beta

Search results, classifications, summaries and AI-assisted assessments may be incomplete, delayed or incorrect.

Check original sources

Do not use EUVIMED results without verification for diagnosis, treatment or other clinical decisions. Always consult the original source and applicable guidelines.

Errors and feedback help us improve EUVIMED: info@euvimed.com

Lokaler Crossref-Datenbestand · journal-article

Advances in linear epitope-based subunit vaccines powered by artificial intelligence: current status and challenges

Jingyu Quan, Lu Liu, Zijian Guo, Tiancheng Shan, Yuhua Shi, Xianbin Cheng

Frontiers in Immunology · 2026

Vollständiger Abstract

Worum geht es in dieser Arbeit?

In this review, linear epitope-based subunit vaccines are systematically profiled to outline their current developmental status, integrating recent advances in computational immunogenic epitope screening, site-specific chemical modification for stability enhancement, next-generation delivery platform matching, and ongoing clinical translation efforts. Deep learning-based MHC-binding prediction tools including NetMHCpan, MHCflurry 2.0, and MARIA, supported by robust empirical evidence, are rigorously evaluated, with notable improvements observed in the efficiency of identifying B/T cell linear epitopes with high immunogenicity, while it is also noted that the field still faces core bottlenecks such as weak in vivo immunogenicity, rapid enzymatic degradation, and insufficient cross-protection against viral variants. According to this integrative evidence-based assessment, feasible optimization pathways are further outlined, including the synergy between AI-driven epitope structural design and virus-like particle-based delivery systems, to provide practical references for the rational development of next-generation broad-spectrum linear epitope-based vaccines.

Bibliografischer Nachweis

Publikationsdaten

Autor:innen
Jingyu Quan, Lu Liu, Zijian Guo, Tiancheng Shan, Yuhua Shi, Xianbin Cheng
Quelle
Frontiers in Immunology
Publikation
2026-01-01
Band / Ausgabe
Nicht angegeben
Seiten
Nicht angegeben
ISSN / ISBN
1664-3224
Zitationen
0 laut Crossref
Referenzen
0 hinterlegt

Zitieren

Zitierfähiger Nachweis

Jingyu Quan, Lu Liu, Zijian Guo, Tiancheng Shan, Yuhua Shi, Xianbin Cheng (2026). Advances in linear epitope-based subunit vaccines powered by artificial intelligence: current status and challenges. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2026.1902723
RIS BibTeX CSL-JSON

Kontext

Themen, Förderung und Nutzung

Lizenzhinweise: Lizenz 1